FDA Clearance Tracker · P990040-S037
TRUFILL n-BCA Liquid Embolic System
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Oct 23, 2026
Approved
Time to decision
263 days
Received Feb 2, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P990040-S037
- Device name
- TRUFILL n-BCA Liquid Embolic System
- Applicant
- Cerenovus, Inc.
- Applicant location
- Miami, FL
- Received
- Feb 2, 2026
- Decided
- Oct 23, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P990040
Device type
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the TRUFILL post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P990040/S034.
Source documents
Other decisions for Cerenovus, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262419 · Decided Aug 14, 2026 · 30 days after receipt
Device type: Device, Neurovascular Embolization (HCG) · Neurology & Neurosurgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.